News
GSK bolsters vaccines division with $3.3bn swoop on Affiniva...
GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated b
